The 3Rs as a framework to support a 21st century approach for nanosafety assessment

Abstract Due to the plethora of nanomaterials being manufactured, it is crucial that their effects on human health are understood. It is not feasible to assess the safety of all nanomaterials using animal-based toxicity tests. There are also scientific, business, legislative and ethical drivers to reconsider the use of such toxicity tests. Utilising non-traditional methods has the potential to improve the human relevance of nanosafety assessment, reduce the numbers of animals that are used, and shift the paradigm to a ‘21st century’ approach that exploits recent scientific and technological advances. This article considers how application of the 3Rs principles can be used as a framework to support and guide this paradigm shift in the short, medium and long-term. Bringing the community together to facilitate the transition is necessary to ensure that tangible impacts are made on the efficiency and robustness of the nanosafety assessment process.

[1]  Elazer R. Edelman,et al.  Science Translational Medicine Podcast: 5 May 2010 , 2010, Science Translational Medicine.

[2]  Melvin E Andersen,et al.  Adverse Outcome Pathways can drive non-animal approaches for safety assessment , 2015, Journal of applied toxicology : JAT.

[3]  J. Bailar,et al.  Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[4]  G. Jenkins,et al.  In vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelines , 2012, Mutation research.

[5]  Nicklas Raun Jacobsen,et al.  Comparative Hazard Identification by a Single Dose Lung Exposure of Zinc Oxide and Silver Nanomaterials in Mice , 2015, PloS one.

[6]  Reinhard Kreiling,et al.  A decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping). , 2015, Regulatory toxicology and pharmacology : RTP.

[7]  M. Wiemann,et al.  Application of short-term inhalation studies to assess the inhalation toxicity of nanomaterials , 2014, Particle and Fibre Toxicology.

[8]  Daniel C Leslie,et al.  A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.

[10]  S. Epstein,et al.  Mutation Research , 1972, Nature.

[11]  J. Bailar,et al.  Toxicity testing in the 21st century—a vision and a strategy , 2012 .

[12]  Peter Wick,et al.  A comparative study of different in vitro lung cell culture systems to assess the most beneficial tool for screening the potential adverse effects of carbon nanotubes. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  Lang Tran,et al.  ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy , 2014, Particle and Fibre Toxicology.